Overview
This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.
Description
Safety evaluations will be conducted over a period of 4 years (±30 days) from the completion date of the parent clinical trial. During the safety follow-up period, participants will be monitored for adverse events, serious adverse events, and other clinically relevant safety parameters to assess the long-term safety profile of Cellgram-ED.
Eligibility
Inclusion Criteria:
- Participants who previously participated in the parent clinical trial and received the cell therapy (Cellgram-ED).
- Participants who have provided written informed consent to participate in this safety follow-up study.
Exclusion Criteria:
